Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients?
celiac disease
compliance
complications
follow-up
gluten-free diet
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
06
02
2022
revised:
28
02
2022
accepted:
10
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Background: Celiac disease (CD) follow-up is a relatively underevaluated topic. However, correct adherence to follow-up procedures is central to the early recognition of complicated CD and other conditions typically associated with CD. Establishing whether patients at increased risk of complications follow clinicians’ recommendations has multiple repercussions. Methods: We retrospectively analyzed the records of patients consecutively diagnosed with CD in our outpatient clinic between January 2004 and October 2017 to investigate the factors associated with drop-out from follow-up procedures. Results: Among the 578 patients analyzed, 40 (6.9%) dropped out during the first six months and 272 (50.6%) during the observation period. The median time to drop-out was 7.4 years (95% confidence interval: 6.8−8.0). No factors were associated with early drop-out. Instead, age at diagnosis >40 years (40−59 years, p < 0.001; ≥60 years, p = 0.048) and classical clinical presentation (p = 0.016) were significantly associated with a lower risk of later drop-out. Conclusions: Patients at increased risk of complicated CD are more compliant with follow-up procedures than patients at lower risk, despite being prescribed the same controls. These results indirectly support the hypothesis of tailored follow-up strategies, differentiated according to the risk of complications.
Identifiants
pubmed: 35334880
pii: nu14061223
doi: 10.3390/nu14061223
pmc: PMC8951498
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Gut. 2015 Aug;64(8):1187-8
pubmed: 25480310
Gut. 2013 Jan;62(1):43-52
pubmed: 22345659
Dig Liver Dis. 2018 Nov;50(11):1189-1194
pubmed: 30025706
Dig Liver Dis. 2018 Jun;50(6):549-552
pubmed: 29277481
Br J Nutr. 2012 Nov 28;108(10):1884-8
pubmed: 22321199
Aliment Pharmacol Ther. 2018 Sep;48(5):538-546
pubmed: 29984415
United European Gastroenterol J. 2019 Jun;7(5):583-613
pubmed: 31210940
World J Gastroenterol. 2022 Jan 7;28(1):154-175
pubmed: 35125825
Aliment Pharmacol Ther. 2015 Feb;41(4):352-9
pubmed: 25581084
Endocr Metab Immune Disord Drug Targets. 2019;19(2):116-120
pubmed: 30033882
J Hepatol. 2015 Jun;62(6):1405-11
pubmed: 25617505
BMC Gastroenterol. 2011 Dec 16;11:136
pubmed: 22176557
Am J Gastroenterol. 2013 May;108(5):656-76; quiz 677
pubmed: 23609613
J Pediatr Gastroenterol Nutr. 2016 Jul;63(1):156-65
pubmed: 27035374
Aliment Pharmacol Ther. 2016 Sep;44(6):612-9
pubmed: 27443825
Clin Nutr. 2019 Feb;38(1):357-363
pubmed: 29306516
J Pediatr. 2017 Apr;183:115-121.e2
pubmed: 28153477
Aliment Pharmacol Ther. 2006 Mar 15;23(6):827-31
pubmed: 16556185
Aliment Pharmacol Ther. 2008 Nov 1;28(9):1042-66
pubmed: 18671779
Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):31-5
pubmed: 20136587
Front Public Health. 2013 Jun 13;1:18
pubmed: 24350187
J Am Diet Assoc. 2003 Nov;103(11):1533-5
pubmed: 14576723
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):412-6
pubmed: 22614110
Digestion. 2012;86(4):309-14
pubmed: 23095439
J Gastroenterol. 2018 Apr;53(4):507-516
pubmed: 28823009
Gastroenterology. 2019 Mar;156(4):885-889
pubmed: 30578783
Aliment Pharmacol Ther. 2017 Jun;45(11):1459-1468
pubmed: 28326597